Brain

Transforming Children’s Lives: DP World’s Aviv Clinics Dubai’s Revolutionary Youth Protocol

DUBAI, United Arab Emirates, July 07, 2024 (GLOBE NEWSWIRE) -- At DP World's Aviv Clinics Dubai, the world’s most advanced…

2 years ago

DP Technology Announces Nomination of Development Candidate, a CNS Penetrable Lp-PLA2 Inhibitor for Alzheimer’s Disease

BEIJING, July 8, 2024 /PRNewswire/ -- DP Technology, an "AI for Science" paradigm-driven company, today announced the nomination of DPT0416,…

2 years ago

IRLAB: Invitation to the Interim Report for Q2 2024 Presentation and Webcast

GOTHENBURG, SE / ACCESSWIRE / July 08, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July 8, 2024 - IRLAB Therapeutics…

2 years ago

Corundum Neuroscience Awards Research Grant to Explore Machine Learning for Non-Invasive Detection of Dementia-Associated Brain Activity During Sleep

Research Project with Tel Aviv University to Focus on Optimizing Identification of Early-Stage Dementia and Improving Diagnosis and Treatment for…

2 years ago

Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024

July 2, 2024 Biodexa Pharmaceuticals PLC Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival…

2 years ago

Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325

Investment will support investigation of Mission's small molecule drug MTX325 in patients with early-stage Parkinson's diseaseMarks latest step in Mission's…

2 years ago

IRLAB’s Phase IIb Study of Pirepemat Can Proceed as Planned after Positive Opinion from External Safety Committee

GOTHENBURG, SWEDEN / ACCESSWIRE / July 2, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July 2, 2024 - IRLAB Therapeutics…

2 years ago

Neuroglee Health Selected for CMS GUIDE Model Program and Announces Company Name Evolution

BOSTON, July 1, 2024 /PRNewswire/ -- Neuroglee Health, a leading cognitive care solutions company,  announced today that it was selected to…

2 years ago

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious…

2 years ago

Achieve Life Sciences Announces Addition to the U.S. Russell 3000® and Russell Microcap® Indexes

SEATTLE and VANCOUVER, British Columbia, July 01, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical…

2 years ago